Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of anlotinib with or without PD-1 blockades in the treatment of advanced primary hepatocellular carcinoma (HCC): A real-world exploratory study.
Authors
Xiao-Qi Chen
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China
Xiao-Qi Chen , Yun-Xia Zhao , Chuan-Lei Zhang , Xin-Ting Wang , Chang-Wei Yuan , Ai-Ying Ji , Xin-Ju Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.432
Abstract #
432
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of anlotinib with PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma: A real-world study.
First Author: Kehe Chen
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness of anlotinib in combination with PD-1 inhibitors as second-line or later therapy for advanced or metastatic esophageal squamous cell carcinoma.
First Author: Yonggui Hong
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of anlotinib combined with TACE among patients with intermediate and advanced-stage hepatocellular carcinoma (HCC).
First Author: Lin Zheng
Poster
2021 ASCO Annual Meeting
Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.
First Author: Qin Xu